| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Levofloxacin N-oxide does not have significant biological activity as it is an inactive metabolite of levofloxacin. It is a degradation product and impurity rather than a pharmacologically active compound. It does not exhibit significant antibacterial activity. The compound is used as an impurity standard and reference material for analytical testing rather than as a therapeutic agent.
|
|---|---|
| ln Vitro |
Levofloxacin N-oxide does not have direct in vitro biological activity as it is an inactive metabolite. It has no significant antibacterial activity. It is used as a reference standard in analytical methods rather than in biological assays. Studies have shown that it has no significant genotoxic risk.
|
| ln Vivo |
Levofloxacin N-oxide does not have in vivo biological activity as it is an inactive metabolite. It is not intended for administration to animals or humans as a therapeutic. Its value is as an analytical standard for pharmaceutical quality control and impurity testing.
|
| Enzyme Assay |
In vitro assays for Levofloxacin N-oxide are primarily analytical rather than biological. HPLC and LC-MS methods are used to detect and quantify the compound as an impurity in levofloxacin drug substance and drug products. Genotoxicity assays may be performed to assess safety, but no significant genotoxic risk has been identified.
|
| Cell Assay |
Cell culture experiments are not applicable to Levofloxacin N-oxide as it is an inactive metabolite and impurity standard. The compound is not used in cell-based assays. Its primary application is in analytical chemistry for pharmaceutical quality control.
|
| Animal Protocol |
In vivo animal experiments are not applicable to Levofloxacin N-oxide as it is an inactive metabolite and impurity standard. The compound is not intended for administration to animals. Its value is as an analytical standard.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Levofloxacin N-oxide as it is an inactive metabolite and impurity standard. The compound is not intended for administration to animals or humans. Its physicochemical properties include molecular weight 377.37 and molecular formula C18H20FN3O5. Storage: appropriately.
|
| Toxicity/Toxicokinetics |
Levofloxacin N-oxide has no significant genotoxic risk. As an impurity, its levels are controlled in pharmaceutical products. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
Levofloxacin N-oxide has CAS number 117678-38-3, molecular formula C18H20FN3O5, and molecular weight 377.37. It is a degradation product and impurity of levofloxacin. It is an inactive metabolite with no significant genotoxic risk. It is used as an impurity standard in pharmaceutical quality control. Not for human use; for research purposes only.
|
| Molecular Formula |
C18H20N3O5F
|
|---|---|
| Molecular Weight |
377.367
|
| Exact Mass |
377.138
|
| CAS # |
117678-38-3
|
| PubChem CID |
10970860
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
678
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[N+]1(CCN(C2=C(F)C=C3C(C(=CN4[C@H](COC2=C34)C)C(=O)O)=O)CC1)[O-]
|
| InChi Key |
MVLAUMUQGRQERL-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C18H20FN3O5/c1-10-9-27-17-14-11(16(23)12(18(24)25)8-21(10)14)7-13(19)15(17)20-3-5-22(2,26)6-4-20/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
|
| Chemical Name |
(2S)-7-fluoro-2-methyl-6-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6499 mL | 13.2496 mL | 26.4992 mL | |
| 5 mM | 0.5300 mL | 2.6499 mL | 5.2998 mL | |
| 10 mM | 0.2650 mL | 1.3250 mL | 2.6499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
